Over forty years of bladder cancer glycobiology: Where do glycans stand facing precision oncology?

ABSTRACT: The high molecular heterogeneity of bladder tumours is responsible for significant variations in disease course, as well as elevated recurrence and progression rates, thereby hampering the introduction of more effective targeted therapeutics. The implementation of precision oncology settings supported by robust molecular models for individualization of patient management is warranted. This effort requires a comprehensive integration of large sets of panomics data that is yet to be fully achieved. Contributing to this goal, over 40 years of bladder cancer glycobiology have disclosed a plethora of cancer-specific glycans and glycoconjugates (glycoproteins, glycolipids, proteoglycans) accompanying disease progressions and dissemination. This review comprehensively addresses the main structura

SUBMITTER: Azevedo R 

PROVIDER: S-EPMC5710962 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature